BPC-157 and Retatrutide for Knee Pain: What the Research Actually Shows

Why weight and knees are linked

Your knee is a hinge. It carries your whole upper body every time your foot hits the ground.

Walking is not gentle on it. The force through a knee with each step is far more than your body weight. When you walk, your leg swings. Your foot lands. Your muscles pull hard to stop the knee folding. All of that stacks up.

So the maths is not one for one. It is much bigger than that.

A study at Wake Forest University followed 142 older adults who were overweight and had knee osteoarthritis. It ran for 18 months. The lead researcher was Stephen Messier. The team measured the real load going through the knee while people walked. They measured it before and after weight loss.

The finding: every single pound of body weight lost took about four pounds off the knee, per step.

That ratio is why weight matters so much for knees. Real numbers make it easier to picture.

The mile figure comes straight from the research team. Losing ten pounds means each knee handles about 48,000 pounds less over a mile walked.

That is the number worth sitting with. No peptide fixes a knee. But this is why weight-loss compounds keep showing up in joint research.

What retatrutide is

Retatrutide is a peptide built to act on three receptors at once. Most weight-loss peptides hit one or two. This one targets GLP-1, GIP and glucagon together.

That is why people call it a triple agonist. Agonist just means it switches a receptor on.

Its phase 2 trial was published in the New England Journal of Medicine by Jastreboff and co-workers. Here is what that trial did.

The results, at the highest dose:

• 17.5% mean body weight reduction at 24 weeks. That is about 41.2 lb, or 18.7 kg.
• 24.2% mean body weight reduction at 48 weeks. That is about 57.8 lb, or 26.2 kg.

One detail from that trial matters more than the headline number. The group had not stopped losing weight when the study ended. The curve was still going down. So 24.2% is where the clock ran out. Not where the effect ran out.

Now put that next to the four-to-one knee number from the section above. A 57 lb loss would take roughly 228 lb of load off each knee, per step.

That is not a claim that retatrutide treats knees. It is just maths on two published findings.

The trial that tested it on knees

Retatrutide’s phase 3 programme is called TRIUMPH. One of those trials was built around this exact question.

TRIUMPH-4 enrolled 445 adults who had both obesity and knee arthritis. It ran 68 weeks. People got 9mg, 12mg or placebo. It reported in December 2025.

Starting weight was about 113 kg. The 12mg group lost roughly 32 kg.

Look at the last row. About one in eight said their knee pain was gone. On placebo it was one in twenty-four.

One caveat, and it matters. These are topline numbers released by the trial sponsor. The full paper has not been published yet. So treat them as reported, not yet peer-reviewed.

The trial that proved the idea

Here is the strongest proof that losing weight this way changes knee pain. It is not from retatrutide. It is from semaglutide, an older drug in the same family.

The trial was called STEP 9. It was published in the New England Journal of Medicine.

The pain score is called WOMAC. Higher means worse. It started at about 70.9 for the group.

Read the two pain numbers again. The placebo group improved too, by 27.5 points. That happens in pain trials. People get better on their own. And knowing you are in a study changes how you report pain.

But the treated group improved by 41.7 points. The gap between the two is the real effect.

That is the cleanest proof in this whole area. Take weight off with a drug in this family, and knee pain scores move. It does not prove retatrutide does the same. It does show the idea is not made up.

What BPC-157 research shows

BPC-157 is where this topic gets loud online. It is also where it needs the most care.

It is a chain of 15 amino acids. The order of them comes from a protein found in stomach fluid. Animal studies have looked at it for tendon, ligament, muscle and gut injury.

Those animal studies are genuinely interesting. Published work has reported effects on tendon cell growth, cell survival and cell movement. This was in lab dishes and in rats. That is why it gets attention.

Now the part that most pages selling it will not put in bold. So we will.

So when you read about BPC-157 for knee pain or BPC-157 for arthritis online, what sits behind it is animal data and personal stories. Both are very different from a trial. It is worth knowing which one you are looking at.

We sell BPC-157 as research material. We will not pretend the proof is better than it is. A lab buying it should know where the science really stands. That is what makes it useful for research.

What the animal work actually looked at

• Tendon models. Rat studies have reported faster healing markers in cut or damaged tendon tissue.
• Cell behaviour. Lab work has reported effects on tendon cell outgrowth, survival and movement.
• Ligament and muscle models. Similar animal work exists, with the same limits.
• Route. Animal studies have used several ways of giving it. What works in a rat is not a plan for anything else.

Cartilage deserves its own note. BPC-157 cartilage repair is a phrase that gets thrown around a lot. Cartilage is slow. It has almost no blood supply. It is very hard to regrow. No human study shows any peptide regrows it. Doubt anything that says it does.

The evidence gap, side by side

These two compounds are at completely different stages. One table makes that obvious.

One column has human results. The other does not. That is the honest summary. It should shape how any study is built around either one.

Why the two get paired

Researchers look at these two together because they act on different problems.

Think of a sore knee as having two separate issues.

Retatrutide research sits on the first problem. BPC-157 research sits on the second.

That is the whole idea behind the pairing. One does not make the other stronger. They are aimed at different things.

Worth saying clearly: no published study has tested these two compounds together. The pairing is a research idea, not a proven plan. Anyone selling you a knee stack protocol is selling a guess.

The weight-loss catch nobody mentions

Here is something that cuts against the simple story. It belongs in an honest guide.

Fast weight loss does not only take off fat. It can take muscle too. The muscle around a knee helps protect it. Your thigh muscles act like a brake and a shock absorber for that joint.

So you can lose weight, lower the load, and still end up with a weaker knee if muscle goes with it. Researchers in this area track lean mass for that reason. It is one of the bigger open questions here.

Where do you inject it for a knee?

This is one of the most searched questions about BPC-157. It deserves a straight answer, not a dodge.

We do not give injection sites, routes or doses for anything we sell. Not for knees. Not for anything else.

That is not us being unhelpful. There are three real reasons.

1. There is no human plan to give. No human trial has set a dose, a route or a site for BPC-157 for anything. Any number you find online was made up, copied from a rat study, or both.
2. Injecting near a joint is not a small thing. A knee joint is a closed space. Putting anything into it or near it carries a real risk of infection. That risk does not care how clean your kitchen table is.
3. It is sold as research material. That is the honest basis for selling it. Telling you how to give it would go against that.

If you are reading this because your knee hurts, the most useful thing on this page is not a product. It is the four-to-one number, and a talk with your doctor about it.

Where TB-500 fits

TB-500 comes up constantly alongside BPC-157. Here is the short version.

TB-500 is related to thymosin beta-4. That is a protein involved in cell movement and tissue repair. Like BPC-157, it has been studied in animals. Like BPC-157, it has no human trials showing it works for joints.

The two are often sold as one blend because their animal research overlaps. A blend is handy for a lab running a single study arm. It is not proof that the mix does anything.

What goes wrong in this area

This corner of the peptide market fails in the same few ways. Here are the ones worth knowing.

• Animal data quoted as human proof. A rat tendon study turns into proven for knees in about three hops online. Always check what animal the study used.
• Before-and-after stories used as evidence. A knee that felt better after eight weeks may have felt better anyway. That is why placebo groups exist. It is why STEP 9 is worth more than a thousand stories.
• Cartilage claims. Regrowing cartilage is one of the hardest problems in medicine. No peptide has been shown to do it in people.
• Dosing charts made up from nothing. A detailed dose chart for something with zero human trials is, by definition, invented.
• No lab report. If a seller cannot show you an outside lab test for the actual lot you are buying, you do not know what is in the vial.
• Athletes not checking the rules. Both BPC-157 and this class of weight-loss drug are banned in tested sport. Anyone competing needs to know that first.

What to check before you buy

If you are buying research material, the checks are the same for every compound.

1. A lab report for your exact lot. Not a general one. Not a photo of a report for some other batch. The lot you are getting.
2. A report you can check yourself. You should be able to go to the testing lab’s own site and confirm the result is real. A PDF anyone could edit proves nothing.
3. Both purity and identity. Purity says how clean it is. Identity says it is the right molecule. You want both tested.
4. Clear storage details. Peptides are fragile. How it was shipped and how it is stored changes what you actually get.
5. Honest wording on the site. A seller making treatment claims about an unapproved compound is telling you how they operate.

Every Red Leaf lot is tested by an outside lab. The reports link straight to that lab’s own page, so you can check them yourself instead of taking our word for it.

Read the lab reports

Retatrutide$79.99 CADBPC-157 (10mg)$75 CADTB-500 (10mg)$84.99 CADBPC-157 / TB-500 20mg$110 CADBacteriostatic Water$10 CADResearch Pen Add-On$99 CAD

Common questions

Bottom line

• The load link is real and measured. One pound off your body is about four pounds off each knee, per step.
• Retatrutide has real human data for weight. 28.7% mean loss at 68 weeks in the knee arthritis trial.
• TRIUMPH-4 tested it on knees and reported. 445 people, 68 weeks, pain scores down 4.5 points against 2.4 on placebo.
• A related compound already moved knee pain scores. STEP 9, 407 people, 68 weeks, a clear gap over placebo.
• BPC-157 has no human trials. Animal work only. Doubt every confident claim about it.
• Nobody has tested the pair together. The pairing is a reason, not a plan.

The most useful things on this page are a ratio from 2005 and two trials, one from 2024 and one from 2025. BPC-157 is the part still being worked out.

Other guides on this site

Research use only. Retatrutide, BPC-157 and TB-500 from Red Leaf Research Labs are not approved for cosmetic, treatment, injection, ingestion or any human or animal use. No claims are made about clinical outcomes, safety or effect. Trial figures are reproduced from published research for reference only and are not guidance of any kind. References: Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med, 2023. Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med, 2024. Messier SP, et al. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum, 2005. United States Anti-Doping Agency, BPC-157 advisory.